Literature DB >> 1439559

Is the irritable gut an inflamed gut?

S M Collins1.   

Abstract

Recent advances in the field of neuroimmunology have provided clear demonstrations of i) the neuromodulation of immune function, and ii) the involvement of the immune system in responses induced by psychologic stress in animals and in man. This has led to speculation about the role of the immune system in psychosocial disease. The irritable bowel syndrome (IBS) is characterized by chronic gastrointestinal dysfunction, which may reflect in altered motility, epithelial function, or sensory perception in the gut. IBS is heterogeneous not only in terms of its clinical presentation but also in terms of its pathogenesis, and factors ranging from psychoneurotic behavior and emotional stress, to dietary fiber deficiency, food intolerance, and enteric infection have been implicated. There is evidence of an increase in the inflammatory cells present in the gut of some IBS patients and in an emerging literature that demonstrates the immunomodulation of the motor system of the gut. These findings invite speculation that the immune system may play a role in the pathogenesis and pathophysiology of at least a subpopulation of IBS patients.

Entities:  

Mesh:

Year:  1992        PMID: 1439559     DOI: 10.3109/00365529209095988

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  16 in total

Review 1.  The functional gastrointestinal disorders and the Rome II process.

Authors:  D A Drossman
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Psychological factors in gastro-oesophageal reflux disease.

Authors:  B T Johnston; S A Lewis; A H Love
Journal:  Gut       Date:  1995-04       Impact factor: 23.059

3.  Henoch-Schonlein purpura leads to functional gastrointestinal disorders.

Authors:  Miguel Saps; Gati Dhroove; Ashish Chogle
Journal:  Dig Dis Sci       Date:  2010-12-04       Impact factor: 3.199

4.  Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: a prospective, randomized trial.

Authors:  J H Liu; G H Chen; H Z Yeh; C K Huang; S K Poon
Journal:  J Gastroenterol       Date:  1997-12       Impact factor: 7.527

Review 5.  Quality of life measurement in gastrointestinal and liver disorders.

Authors:  M R Borgaonkar; E J Irvine
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

Review 6.  Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review.

Authors:  Alexander C Ford; Nicholas J Talley
Journal:  J Gastroenterol       Date:  2011-02-18       Impact factor: 7.527

7.  Irritable bowel syndrome, gastro-oesophageal reflux, and bronchial hyper-responsiveness in the general population.

Authors:  T M Kennedy; R H Jones; A P Hungin; H O'flanagan; P Kelly
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

8.  Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome.

Authors:  Olafur S Palsson; Olivier Morteau; Eugene M Bozymski; John T Woosley; R Balfour Sartor; Michael J Davies; David A Johnson; Marsha J Turner; William E Whitehead
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

Review 9.  Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy.

Authors:  Massimo Bellini; Dario Gambaccini; Cristina Stasi; Maria Teresa Urbano; Santino Marchi; Paolo Usai-Satta
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

10.  Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation.

Authors:  Rebeca Martín; Florian Chain; Sylvie Miquel; Jane M Natividad; Harry Sokol; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  Hum Vaccin Immunother       Date:  2014-04-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.